Your session is about to expire
← Back to Search
Pimavanserin for Neuropsychiatric Symptoms
Study Summary
This trial will study the safety and tolerability of the drug pimavanserin when taken by adults and elderly patients with neuropsychiatric symptoms related to neurodegenerative diseases, over the course of 52 weeks.
- Neuropsychiatric Symptoms of Neurodegenerative Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 6 Patients • NCT04188392Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA given Pimavanserin their blessing?
"Pimavanserin's safety is well supported by multiple clinical trials and Phase 3 data, so it received a score of 3."
Are there any other instances of Pimavanserin being studied in a clinical setting?
"At this moment in time, there are 6 ongoing studies involving Pimavanserin. 3 of these live studies are currently in Phase 3 clinical trials. The majority of the research for Pimavanserin takes place in Gdańsk and Arizona; however, 414 different locations around the world are running trials for this treatment."
Are there any available places for patients in this research project?
"This is an inactive clinical trial, which was originally posted on July 17th, 2018. The last update to the listing was on October 10th, 2022. There are 56 other trials that may be a better match for patients right now."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger